CHA.35680
(S)-ZINC-3573
--
--
Ordering
Available Variants5 mg
CHA.35680-5mg
Price
€89.60
Available – Dispatch in 14 days
50 mg
CHA.35680-50mg
Price
€34.64
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.35680-5mg | €89.60 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.35680-50mg | €34.64 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C18H21N5 |
|---|---|
| CAS Number | 2095596-11-3 |
| Molecular Weight | 307.39 |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS07
GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H315 |
| pcodes | P264 - P280 - P302 + P352 - P332 + P313 - P362 + P364 |
| Hazard Classifications | Skin Irrit. 2 |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Sorafenib tosylate, with a chemical formula of C21H23ClN4O3 and a molecular weight of 424.9 g/mol, is a multikinase inhibitor used in the treatment of various cancers, including renal cell carcinoma and hepatocellular carcinoma. The compound, identified by the CAS number 284461-73-0, functions by inhibiting the activity of multiple intracellular and cell surface kinases, which are enzymes that play critical roles in tumor growth and angiogenesis. Sorafenib tosylate has been shown to exhibit anti-proliferative and anti-angiogenic effects, leading to the inhibition of tumor growth and metastasis. Its pharmacokinetic properties allow for oral administration, with a bioavailability of approximately 38-49% and a half-life of around 25-48 hours, enabling once-daily dosing. The compounds efficacy and safety have been established in clinical trials, making it a valuable therapeutic option for patients with advanced cancers.
